Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
174M
-
Number of holders
-
161
-
Total 13F shares, excl. options
-
92.3M
-
Shares change
-
+33.7M
-
Total reported value, excl. options
-
$512M
-
Value change
-
+$187M
-
Put/Call ratio
-
0.71
-
Number of buys
-
112
-
Number of sells
-
-37
-
Price
-
$5.54
Significant Holders of Prime Medicine, Inc. - COMMON STOCK (PRME) as of Q3 2025
181 filings reported holding PRME - Prime Medicine, Inc. - COMMON STOCK as of Q3 2025.
Prime Medicine, Inc. - COMMON STOCK (PRME) has 161 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 92.3M shares
of 174M outstanding shares and own 52.99% of the company stock.
Largest 10 shareholders include Alphabet Inc. (16.6M shares), T. Rowe Price Investment Management, Inc. (9.22M shares), BlackRock, Inc. (5.65M shares), ARK Investment Management LLC (5.48M shares), VANGUARD GROUP INC (4.92M shares), FARALLON CAPITAL MANAGEMENT LLC (4.75M shares), Amova Asset Management Americas, Inc. (3.63M shares), Sumitomo Mitsui Trust Group, Inc. (3.63M shares), Casdin Capital, LLC (3.17M shares), and Woodline Partners LP (3M shares).
This table shows the top 161 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.